Referências

Principais artigos

Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus; Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z, et al. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med. 2008;358:261-273.Texto completo  Resumo

World Health Organization. WHO guidelines for pharmacological management of pandemic (H1N1) 2009 influenza and other influenza viruses. February 2010 [internet publication].Texto completo

World Health Organization. WHO rapid advice guidelines on pharmacological management of humans infected with avian influenza A (H5N1) virus. June 2006 [internet publication].Texto completo

Centers for Disease Control and Prevention. Interim guidance on follow-up of close contacts of persons infected with novel influenza A viruses associated with severe human disease and on the use of antiviral medications for chemoprophylaxis. Apr 2015 [internet publication].Texto completo

World Health Organization. Infection control recommendations for avian influenza in health-care facilities. 2006 [internet publication].Texto completo

Centers for Disease Control and Prevention. Influenza antiviral medications: summary for clinicians. Oct 2020 [internet publication].Texto completo

Artigos de referência

1. Ungchusak K, Auewarakul P, Dowell SF, et al. Probable person-to-person transmission of avian influenza A (H5N1). N Engl J Med. 2005;352:333-340.Texto completo  Resumo

2. Wang H, Feng Z, Shu Y, et al. Probable limited person-to-person transmission of highly pathogenic avian influenza A (H5N1) virus in China. Lancet. 2008;371:1427-1434. Resumo

3. Skowronski DM, Tweed SA, Petric M, et al. Human illness and isolation of low-pathogenicity avian influenza virus of the H7N3 subtype in British Columbia, Canada. J Infect Dis. 2006;193:899-900. Resumo

4. Peiris M, Yuen KY, Leung CW, et al. Human infection with influenza H9N2. Lancet. 1999;354:916-917. Resumo

5. Uyeki TM, Chong YH, Katz JM, et al. Lack of evidence for human-to-human transmission of avian influenza A (H9N2) viruses in Hong Kong, China 1999. Emerg Infect Dis. 2002;8:154-159.Texto completo  Resumo

6. Eurosurveillance editorial team. Avian influenza A/(H7N2) outbreak in the United Kingdom. Euro Surveill. 2007;12:pii=3206.Texto completo  Resumo

7. Kurtz J, Manvell RJ, Banks J. Avian influenza virus isolated from a woman with conjunctivitis. Lancet. 1996;348:901-902. Resumo

8. Tweed SA, Skowronski DM, David ST, et al. Human illness from avian influenza H7N3, British Columbia. Emerg Infect Dis. 2004;10:2196-2199.Texto completo  Resumo

9. Nguyen-Van-Tam JS, Nair P, Acheson P, et al. Outbreak of low pathogenicity H7N3 avian influenza in UK, including associated case of human conjunctivitis. Euro Surveill. 2006;11:pii=2952.Texto completo  Resumo

10. Pan M, Gao R, Lv Q, et al. Human infection with a novel, highly pathogenic avian influenza A (H5N6) virus: virological and clinical findings. J Infect. 2016;72:52-59. Resumo

11. Yang ZF, Mok CK, Peiris JS, et al. Human infection with a novel avian influenza A (H5N6) virus. N Engl J Med. 2015;373:487-489.Texto completo  Resumo

12. World Health Organization/World Organisation for Animal Health/Food and Agriculture Organization H5N1 Evolution Working Group. Revised and updated nomenclature for highly pathogenic avian influenza A (H5N1) viruses. Influenza Other Respir Viruses. 2014;8:384-388.Texto completo  Resumo

13. World Health Organization. Evolution of the influenza A(H5) haemagglutinin: WHO/OIE/FAO H5 Working Group reports a new clade designated 2.3.4.4. January 2015 [internet publication].Texto completo

14. Smith GJ, Donis RO; World Health Organization/World Organisation for Animal Health/Food and Agriculture Organization (WHO/OIE/FAO) H5 Evolution Working Group. Nomenclature updates resulting from the evolution of avian influenza A(H5) virus clades 2.1.3.2a, 2.2.1, and 2.3.4 during 2013-2014. Influenza Other Respir Viruses. 2015;9:271-276.Texto completo  Resumo

15. World Health Organization. Antigenic and genetic characteristics of influenza A(H5N1) and influenza A(H9N2) viruses and candidate vaccine viruses developed for potential use in human vaccines: February 2010. Wkly Epidemiol Rec. 2010;85:100-107.Texto completo

16. Nguyen T, Rivailler P, Davis CT, et al. Evolution of highly pathogenic avian influenza (H5N1) virus populations in Vietnam between 2007 and 2010. Virology. 2012;432:405-416. Resumo

17. Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus; Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z, et al. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med. 2008;358:261-273.Texto completo  Resumo

18. World Health Organization. Update on human cases of highly pathogenic avian influenza A(H5N1) virus infection, 2010. Wkly Epidemiol Rec. 2011;86:161-166.Texto completo  Resumo

19. Uyeki TM. Human infection with highly pathogenic avian influenza A (H5N1) virus: review of clinical issues. Clin Infect Dis. 2009;49:279-290.Texto completo  Resumo

20. de Jong MD, Bach VC, Phan TQ, et al. Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma. N Engl J Med. 2005;352:686-691.Texto completo  Resumo

21. Rajabali N, Lim T, Sokolowski C, et al. Avian influenza A (H5N1) infection with respiratory failure and meningoencephalitis in a Canadian traveller. Can J Infect Dis Med Microbiol. 2015;26:221-223.Texto completo  Resumo

22. Kandeel A, Manoncourt S, Abd el Kareem E, et al. Zoonotic transmission of avian influenza virus (H5N1), Egypt, 2006-2009. Emerg Infect Dis. 2010;16:1101-1107.Texto completo  Resumo

23. International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR,B). Outbreak of mild respiratory disease caused by H5N1 and H9N2 infections among young children in Dhaka, Bangladesh, 2011. Health Sci Bulletin. 2011;9:1-12.Texto completo

24. Oner AF, Dogan N, Gasimov V, et al. H5N1 avian influenza in children. Clin Infect Dis. 2012;55:26-32.Texto completo  Resumo

25. Shinde V, Hanshaoworakul W, Simmerman JM, et al. A comparison of clinical and epidemiological characteristics of fatal human infections with H5N1 and human influenza viruses in Thailand, 2004-2006. PLoS One. 2011;6:e14809.Texto completo  Resumo

26. World Health Organization. Cumulative number of confirmed human cases of avian influenza A(H5N1) reported to WHO. 2018 [internet publication].Texto completo

27. World Health Organization. Information on avian influenza A (H5N1) identified in human in Nepal. May 2019 [internet publication].Texto completo

28. World Health Organization. Avian Influenza A(H5N1)- Lao People's Democratic Republic. Nov 2020 [internet publication].Texto completo

29. World Health Organization. Update: WHO-confirmed human cases of avian influenza A (H5N1) infection, November 2003-May 2008. Wkly Epidemiol Rec. 2008;83:415-420.Texto completo  Resumo

30. Centers for Disease Control and Prevention. Highly pathogenic Asian avian influenza A (H5N1) virus. May 2018 [internet publication].Texto completo

31. Food and Agriculture Organization of the United Nations. Update on the continuous spread and expansion of H5N1 highly pathogenic avian influenza: clade 2.3.2.1 in Asia (2010-2012). January 2014 [internet publication].Texto completo

32. Qi Y, Ni HB, Chen X, et al. Seroprevalence of highly pathogenic avian influenza (H5N1) virus infection among humans in mainland China: A systematic review and meta-analysis. Transbound Emerg Dis. 2020 Apr 7 [Epub ahead of print]. Resumo

33. Gomaa MR, El Rifay AS, Abu Zeid D, et al. Incidence and seroprevalence of avian influenza in a cohort of backyard poultry growers, Egypt, August 2015-March 2019. Emerg Infect Dis. 2020 Sep;26(9):2129-36.Texto completo  Resumo

34. Centers for Disease Control and Prevention. Highly pathogenic avian influenza A (H5N1) in birds and other animals. Jan 2015 [internet publication].Texto completo

35. Tong S, Zhu X, Li Y, et al. New world bats harbor diverse influenza A viruses. PLoS Pathog. 2013;9:e1003657.Texto completo  Resumo

36. Areechokchai D, Jiraphongsa C, Laosiritaworn Y, et al. Investigation of avian influenza (H5N1) outbreak in humans: Thailand, 2004. MMWR Morb Mortal Wkly Rep. 2006;55(suppl 1):3-6.Texto completo  Resumo

37. Dinh PN, Long HT, Tien NT, et al. Risk factors for human infection with avian influenza A H5N1, Vietnam, 2004. Emerg Infect Dis. 2006;12:1841-1847.Texto completo  Resumo

38. World Health Organization. Update on human cases of highly pathogenic avian influenza A(H5N1) virus infection, 2011. WHO Wkly Epidemiolog Rec. 2012;87:117-128.Texto completo

39. Mounts AW, Kwong H, Izurieta HS, et al. Case-control study of risk factors for avian influenza A (H5N1) disease, Hong Kong, 1997. J Infect Dis. 1999;180:505-508. Resumo

40. Zhou L, Liao Q, Dong L, et al. Risk factors for human illness with avian influenza A (H5N1) virus infection in China. J Infect Dis. 2009;199:1726-1734. Resumo

41. Wan XF, Dong L, Lan Y, et al. Indications that live poultry markets are a major source of human H5N1 influenza virus infection in China. J Virol. 2011;85:13432-13438.Texto completo  Resumo

42. Kandun IN, Tresnaningsih E, Purba WH, et al. Factors associated with case fatality of human H5N1 virus infections in Indonesia: a case series. Lancet. 2008;372:744-749. Resumo

43. Horby P, Sudoyo H, Viprakasit V, et al. What is the evidence of a role for host genetics in susceptibility to influenza A/H5N1? Epidemiol Infect. 2010;138:1550-1558.Texto completo  Resumo

44. Human cases of avian influenza A (H5N1) in North-West Frontier Province, Pakistan, October-November 2007. Wkly Epidemiol Rec. 2008;83:359-364. Resumo

45. Aditama TY, Samaan G, Kusriastuti R, et al. Risk factors for cluster outbreaks of avian influenza A H5N1 infection, Indonesia. Clin Infect Dis. 2011;53:1237-1244.Texto completo  Resumo

46. Aditama TY, Samaan G, Kusriastuti R, et al. Avian influenza H5N1 transmission in households, Indonesia. PLoS One. 2012;7:e29971.Texto completo  Resumo

47. Kandun IN, Wibisono H, Sedyaningsih ER, et al. Three Indonesian clusters of H5N1 virus infection in 2005. N Engl J Med. 2006;355:2186-2194.Texto completo  Resumo

48. Beigel JH, Farrar J, Han AM, et al. Avian influenza A (H5N1) infection in humans. N Engl J Med. 2005;353:1374-1385.Texto completo  Resumo

49. Imai M, Watanabe T, Hatta M, et al. Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature. 2012;486:420-428.Texto completo  Resumo

50. Neumann G, Macken CA, Karasin AI, et al. Egyptian H5N1 influenza viruses-cause for concern? PLoS Pathog. 2012;8:e1002932.Texto completo  Resumo

51. Russell CA, Fonville JM, Brown AE, et al. The potential for respiratory droplet-transmissible A/H5N1 influenza virus to evolve in a mammalian host. Science. 2012;336:1541-1547.Texto completo  Resumo

52. Uyeki TM, Bresee JS. Detecting human-to-human transmission of avian influenza A (H5N1). Emerg Infect Dis. 2007;13:1969-1971.Texto completo  Resumo

53. Refaey S, Azziz-Baumgartner E, Amin MM, et al. Increased number of human cases of influenza virus A(H5N1) infection, Egypt, 2014-15. Emerg Infect Dis. 2015;21:2171-2173.Texto completo  Resumo

54. Le MQ, Horby P, Fox A, et al. Subclinical avian influenza A(H5N1) virus infection in human, Vietnam. Emerg Infect Dis. 2013;19:1674-1677.Texto completo  Resumo

55. Garten RJ, Davis CT, Russell CA, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science. 2009;325:197-201.Texto completo  Resumo

56. Horimoto T, Kawaoka Y. Influenza: lessons from past pandemics, warnings from current incidents. Nat Rev Microbiol. 2005;3:591-600. Resumo

57. Yamada S, Suzuki Y, Suzuki T, et al. Haemagglutinin mutations responsible for the binding of H5N1 influenza A viruses to human-type receptors. Nature. 2006;444:378-382. Resumo

58. van Riel D, Munster VJ, de Wit E, et al. H5N1 virus attachment to lower respiratory tract. Science. 2006;312:399.Texto completo  Resumo

59. Shu Y, Li CK, Li Z, et al. Avian influenza A(H5N1) viruses can directly infect and replicate in human gut tissues. J Infect Dis. 2010;201:1173-1177. Resumo

60. Chandrasekaran A, Srinivasan A, Raman R, et al. Glycan topology determines human adaptation of avian H5N1 virus hemagglutinin. Nat Biotechnol. 2008;26:107-113. Resumo

61. Auewarakul P, Suptawiwat O, Kongchanagul A, et al. An avian influenza H5N1 virus that binds to a human-type receptor. J Virol. 2007;81:9950-9955.Texto completo  Resumo

62. Chan MC, Cheung CY, Chui WH, et al. Proinflammatory cytokine responses induced by influenza A (H5N1) viruses in primary human alveolar and bronchial epithelial cells. Respir Res. 2005;6:135.Texto completo  Resumo

63. de Jong MD, Simmons CP, Thanh TT, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med. 2006;12:1203-1207. Resumo

64. Gu J, Xie Z, Gao Z, et al. H5N1 infection of the respiratory tract and beyond: a molecular pathology study. Lancet. 2007;370:1137-1145. Resumo

65. Cavailler P, Chu S, Ly S, et al. Seroprevalence of anti-H5 antibody in rural Cambodia, 2007. J Clin Virol. 2010;48:123-126. Resumo

66. Apisarnthanarak A, Erb S, Stephenson I, et al. Seroprevalence of anti-H5 antibody among Thai health care workers after exposure to avian influenza (H5N1) in a tertiary care center. Clin Infect Dis. 2005;40:e16-e18. Resumo

67. Liem NT, Lim W. Lack of H5N1 avian influenza transmission to hospital employees, Hanoi, 2004. Emerg Infect Dis. 2005;11:210-215.Texto completo  Resumo

68. Schultsz C, Dong VC, Chau NV, et al. Avian influenza H5N1 and healthcare workers. Emerg Infect Dis. 2005;11:1158-1159.Texto completo  Resumo

69. World Health Organization. WHO laboratory biosafety guidelines for handling specimens suspected of containing avian influenza A virus. January 2005 [internet publication].Texto completo

70. Ortiz JR, Katz MA, Mahmoud MN, et al. Lack of evidence of avian-to-human transmission of avian influenza A (H5N1) virus among poultry workers, Kano, Nigeria, 2006. J Infect Dis. 2007;196:1685-1691. Resumo

71. Prieto-Lara E, Llanos-Mendez A. Safety and immunogenicity of prepandemic H5N1 influenza vaccines: a systematic review of the literature. Vaccine. 2010;28:4328-4334. Resumo

72. Vesikari T, Forstén A, Herbinger KH, et al. Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly. Vaccine. 2012;30:1388-1396. Resumo

73. Langley JM, Risi G, Caldwell M, et al. Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study. J Infect Dis. 2011;203:1729-1738.Texto completo  Resumo

74. US Food and Drug Administration. Influenza virus vaccine, H5N1 (for national stockpile). February 2018 [internet publication].Texto completo

75. Qualls N, Levitt A, Kanade N, et al; CDC Community Mitigation Guidelines Work Group. Community mitigation guidelines to prevent pandemic influenza - United States, 2017. MMWR Recomm Rep. 2017;66:1-34.Texto completo  Resumo

76. Centers for Disease Control and Prevention. Interim guidance for specimen collection, processing, and testing for patients with suspected infection with novel influenza A viruses associated with severe disease in humans. May 2014 [internet publication].Texto completo

77. World Health Organization. Collecting, preserving and shipping specimens for the diagnosis of avian influenza A(H5N1) virus infection. October 2006 [internet publication].Texto completo

78. World Health Organization. Clinical management of human infection with avian influenza A (H5N1) virus. August 2007 [internet publication].Texto completo

79. World Health Organization. Recommendations and laboratory procedures for detection of avian influenza A(H5N1) virus in specimens from suspected human cases. August 2007 [internet publication].Texto completo

80. World Health Organization. WHO criteria for accepting positive PCR test results of H5 infection in humans from national reference laboratories. May 2011 [internet publication].Texto completo

81. World Health Organization. WHO accepts positive PCR test results of H5 infection in humans from the following laboratories. May 2011 [internet publication].Texto completo

82. World Health Organization. WHO reference laboratories for diagnosis of influenza A/H5 infection. May 2017 [internet publication].Texto completo

83. Powell TJ, Fox A, Peng Y, et al. Identification of H5N1-specific T-cell responses in a high-risk cohort in Vietnam indicates the existence of potential asymptomatic infections. J Infect Dis. 2012;205:20-27. Resumo

84. American Academy of Pediatrics. Respiratory syncytial virus. In: Pickering LK, ed. Red book: 2006 report of the Committee on Infectious Diseases, 27th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2006:561.

85. Centers for Disease Control and Prevention. Interim guidance on case definitions for investigations of human infection with highly pathogenic avian influenza A (H5N1) virus in the United States. January 2016 [internet publication].Texto completo

86. World Health Organization. WHO case definitions for human infections with influenza A(H5N1) virus. August 2006 [internet publication].Texto completo

87. Schunemann HJ, Hill SR, Kakad M, et al. WHO rapid advice guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. Lancet Infect Dis. 2007;7:21-31. Resumo

88. World Health Organization. WHO guidelines for pharmacological management of pandemic (H1N1) 2009 influenza and other influenza viruses. February 2010 [internet publication].Texto completo

89. World Health Organization. WHO rapid advice guidelines on pharmacological management of humans infected with avian influenza A (H5N1) virus. June 2006 [internet publication].Texto completo

90. Centers for Disease Control and Prevention. Interim guidance on follow-up of close contacts of persons infected with novel influenza A viruses associated with severe human disease and on the use of antiviral medications for chemoprophylaxis. Apr 2015 [internet publication].Texto completo

91. Patel RB, Mathur MB, Gould M, et al. Demographic and clinical predictors of mortality from highly pathogenic avian influenza A (H5N1) virus infection: CART analysis of international cases. PLoS One. 2014;9:e91630.Texto completo  Resumo

92. Arabi Y, Gomersall CD, Ahmed QA, et al. The critically ill avian influenza A (H5N1) patient. Crit Care Med. 2007;35:1397-1403. Resumo

93. Adisasmito W, Chan PK, Lee N, et al. Effectiveness of antiviral treatment in human influenza A (H5N1) infections: analysis of a Global Patient Registry. J Infect Dis. 2010;202:1154-1160.Texto completo  Resumo

94. Chan PK, Lee N, Zaman M, et al. Determinants of antiviral effectiveness in influenza virus A subtype H5N1. J Infect Dis. 2012;206:1359-1366. Resumo

95. de Jong MD, Tran TT, Truong HK, et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med. 2005;353:2667-2672.Texto completo  Resumo

96. Le QM, Kiso M, Someya K, et al. Avian flu: isolation of drug-resistant H5N1 virus. Nature. 2005;437:1108. Resumo

97. Le MT, Wertheim HF, Nguyen HD, et al. Influenza A H5N1 clade 2.3.4 virus with a different antiviral susceptibility profile replaced clade 1 virus in humans in northern Vietnam. PLoS One. 2008;3:e3339.Texto completo  Resumo

98. Duval X, van der Werf S, Blanchon T, et al. Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. PLoS Med. 2010;7:e1000362.Texto completo  Resumo

99. World Health Organization. Infection control recommendations for avian influenza in health-care facilities. 2006 [internet publication].Texto completo

100. Centers for Disease Control and Prevention. Influenza antiviral medications: summary for clinicians. Oct 2020 [internet publication].Texto completo

101. American Academy of Pediatrics Committee on Infectious Diseases. Recommendations for prevention and control of influenza in children, 2013-2014. Pediatrics. 2013;132:e1089-e1104.Texto completo  Resumo

102. Kayali G, Webby RJ, Ducatez MF, et al. The epidemiological and molecular aspects of influenza H5N1 viruses at the human-animal interface in Egypt. PLoS One. 2011;6:e17730.Texto completo  Resumo

103. Fiebig L, Soyka J, Buda S, et al. Avian influenza A(H5N1) in humans: new insights from a line list of World Health Organization confirmed cases, September 2006 to August 2010. Euro Surveill. 2011;16:19941. Resumo

104. Taylor WR, Thinh BN, Anh GT, et al. Oseltamivir is adequately absorbed following nasogastric administration to adult patients with severe H5N1 influenza. PLoS One. 2008;3:e3410.Texto completo  Resumo

105. Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med. 2007;357:1450-1451.Texto completo  Resumo

106. Yu H, Gao Z, Feng Z, et al. Clinical characteristics of 26 human cases of highly pathogenic avian influenza A (H5N1) virus infection in China. PLoS One. 2008;3:e2985.Texto completo  Resumo

107. Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J infect Dis. 2015;211:80-90.Texto completo  Resumo

108. Ikematsu H, Kawai N. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza. Expert Rev Anti Infect Ther. 2011;9:851-857. Resumo

109. Ilyushina NA, Hay A, Yilmaz N, et al. Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice. Antimicrob Agents Chemother. 2008;52:3889-3897.Texto completo  Resumo

110. Muller MP, Dresser L, Raboud J, et al. Adverse events associated with high-dose ribavirin: evidence from the Toronto outbreak of severe acute respiratory syndrome. Pharmacotherapy. 2007;27:494-503. Resumo

111. Lee N, Chan PK, Hui DS, et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis. 2009;200:492-500. Resumo

112. Han K, Ma H, An X, et al. Early use of glucocorticoids was a risk factor for critical disease and death from pH1N1infection. Clin Infect Dis. 2011;53:326-333. Resumo

113. Lee CM, Hudson LD. Long-term outcomes after ARDS. Semin Respir Crit Care Med. 2001;22:327-336. Resumo

114. Ehlenbach WJ, Hough CL, Crane PK, et al. Association between acute care and critical illness hospitalization and cognitive function in older adults. JAMA. 2010;303:763-770.Texto completo  Resumo

O uso deste conteúdo está sujeito ao nosso aviso legal